Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Apellis Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Apellis Pharmaceuticals serves clients worldwide.
Website: apellis.com


  • Good financial results growth rate 166.5% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (70.5%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 3.6% (LTM)
  • Share price is 28.1% higher than minimum and 77.5% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (14.2x vs 17.5x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.9 mln (-0.038% of cap.)

Key Financials (Download financials)

Ticker: APLS
Share price, USD:  (+2.3%)20.95
year average price 22.79  


year start price 30.39 2025-01-22

max close price 30.76 2025-01-23

min close price 16.36 2025-05-15

current price 20.47 2026-01-21
Common stocks: 107 196 299

Dividend Yield:  0.0%
FCF Yield LTM: 3.6%
EV / LTM EBITDA: 14.2x
EV / EBITDA annualized: 2.4x
EV / Sales: 2.2x
Margin (EBITDA LTM / Revenue): 15.1%

Target EV / EBITDA (hist percentile): 17.5x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 2 194
Net Debt ($m): -4
EV (Enterprise Value): 2 190
EBITDA LTM (млн $): 154
EV / LTM EBITDA: 14.2x
Price to Book: 5.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-17247wallst.com

Is Apellis Pharmaceuticals' FDA Win Just the Beginning?

2026-01-12seekingalpha.com

Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-03globenewswire.com

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

2025-11-12seekingalpha.com

Apellis Pharmaceuticals, Inc. (APLS) Presents at Stifel 2025 Healthcare Conference Transcript

2025-10-30seekingalpha.com

Apellis Pharmaceuticals, Inc. (APLS) Q3 2025 Earnings Call Transcript

2025-10-30zacks.com

Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates

2025-09-30seekingalpha.com

Apellis Pharmaceuticals: Maintaining "Buy" Rating With Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders

2025-08-14seekingalpha.com

Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval

2025-08-02seekingalpha.com

Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript

2025-08-01seekingalpha.com

Apellis Pharmaceuticals: The Picture Becomes Clearer
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-31 2024-11-05 2024-08-01 2024-05-07 2023-11-01 2023-07-31 2023-05-04 2022-11-07
acceptedDate 2025-10-30 06:57:30 2025-07-31 06:52:59 2025-02-28 07:00:18 2024-11-05 06:57:32 2024-08-01 07:02:24 2024-05-07 07:02:51 2024-02-27 07:01:54 2023-11-01 07:02:15 2023-07-31 16:07:17 2023-05-04 16:02:25 2023-02-21 16:09:51 2022-11-07 16:13:20 2022-02-28 16:06:11 2021-02-25 16:01:27
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 459M 178M 781M 197M 200M 172M 397M 99M 95M 45M 75M 22M 67M 251M
costOfRevenue 25M 14M 118M 34M 24M 21M 59M 22M 8M 8M 6M 1M 5M 25M
grossProfit 434M 164M 664M 163M 176M 152M 338M 77M 87M 37M 70M 21M 61M 226M
grossProfitRatio 0.947 0.921 0.83 0.882 0.88 0.774 0.912 0.826 0.937
researchAndDevelopmentExpenses 68M 67M 328M 89M 78M 85M 354M 79M 96M 110M 387M 95M 421M 300M
generalAndAdministrativeExpenses 0 0 418M 0 0 0 501M 146M 111M 102M 277M 78M 177M 139M
sellingAndMarketingExpenses 0 0 83M 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 143M 131M 501M 122M 128M 129M 501M 146M 111M 102M 277M 78M 177M 139M
otherExpenses 0 0 0 0 24 000 -499 000 0 -603 000 -63 000 -277 000 -288 000 0 1M -501 000
operatingExpenses 211M 198M 829M 211M 206M 214M 855M 225M 207M 212M 664M 174M 598M 439M
costAndExpenses 235M 212M 946M 244M 229M 234M 914M 247M 215M 220M 670M 175M 603M 464M
interestIncome 4M 3M 13M 3M 3M 3M 21M 5M 6M 5M 9M 3M 418 000 4M
interestExpense 11M 11M 40M 13M 9M 7M 30M -7M 7M 8M 33M 8M 13M 30M
depreciationAndAmortization 339 000 446 000 2M 621 000 449 000 444 000 2M 405 000 410 000 6M 1M 3M 1M 859 000
ebitda 228M -30M -155M -44M -28M -62M -495M -148M -115M -170M -617M -150M -731M -312M
ebitdaratio 0.497 -0.169 -0.223 -0.145 -0.358 -1.495 -1.206 -3.781 -6.786
operatingIncome 223M -33M -165M -47M -29M -62M -517M -148M -120M -175M -595M -153M -536M -214M
operatingIncomeRatio 0.487 -0.186 -0.24 -0.147 -0.36 -1.495 -1.268 -3.904 -6.934
totalOtherIncomeExpensesNet -7M -8M -32M -10M -8M -4M -9M 8M -63 000 -2M -57M -38M -210M -129M
incomeBeforeTax 216M -42M -197M -57M -38M -66M -526M -140M -122M -177M -652M -191M -746M -343M
incomeBeforeTaxRatio 0.472 -0.234 -0.289 -0.188 -0.384 -1.412 -1.283 -3.958 -8.652
incomeTaxExpense 602 000 466 000 1M 592 000 114 000 170 000 2M 233 000 194 000 282 000 669 000 446 000 352 000 2M
netIncome 216M -42M -198M -57M -38M -66M -529M -140M -122M -178M -652M -191M -746M -345M
netIncomeRatio 0.47 -0.236 -0.292 -0.189 -0.385 -1.414 -1.285 -3.964 -8.672
eps 1.71 -0.33 -1.6 -0.46 -0.3 -0.54 -4.45 -1.17 -1.02 -1.56 -6.15 -1.75 -8.84 -4.59
epsdiluted 1.71 -0.33 -0.46 -0.3 -0.54 -1.17 -1.02 -1.56 -1.75
weightedAverageShsOut 126M 126M 124M 124M 124M 123M 119M 120M 119M 114M 106M 109M 84M 75M
weightedAverageShsOutDil 126M 126M 124M 124M 124M 123M 119M 120M 119M 114M 106M 109M 84M 75M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-27 2023-02-21 2022-02-28 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -28M -9M -24M -13M -26M
ebit -156M -497M -619M -733M -313M
nonOperatingIncomeExcludingInterest -9M -20M 24M 196M 99M
netIncomeFromContinuingOperations -198M -529M -652M -746M -345M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -198M -529M -652M -746M -345M
epsDiluted -1.6 -4.45 -6.15 -8.84 -4.59

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-31 2024-11-05 2024-08-01 2024-05-07 2023-11-01 2023-07-31 2023-05-04 2022-11-07
acceptedDate 2025-10-30 06:57:30 2025-07-31 06:52:59 2025-02-28 07:00:18 2024-11-05 06:57:32 2024-08-01 07:02:24 2024-05-07 07:02:51 2024-02-27 07:01:54 2023-11-01 07:02:15 2023-07-31 16:07:17 2023-05-04 16:02:25 2023-02-21 16:09:51 2022-11-07 16:13:20 2022-02-28 16:06:11 2021-02-25 16:01:27
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 479M 371M 411M 397M 361M 327M 351M 452M 616M 765M 552M 584M 640M 566M
shortTermInvestments 0 0 5M 0 8M 8M 1M 13M 9M 0 0 124M 61M 312M
cashAndShortTermInvestments 479M 371M 416M 397M 361M 327M 352M 452M 616M 765M 552M 709M 701M 878M
netReceivables 355M 229M 272M 284M 309M 268M 206M 187M 111M 32M 8M 8M 80M 25M
inventory 123M 121M 82M 121M 153M 161M 146M 99M 103M 85M 86M 60M 24M 0
otherCurrentAssets 34M 34M 9M 32M 37M 55M 22M 13M 27M 34M 37M 24M 14M 11M
totalCurrentAssets 991M 756M 789M 834M 860M 811M 766M 797M 893M 954M 720M 832M 824M 917M
propertyPlantEquipmentNet 22M 17M 19M 20M 20M 19M 21M 20M 22M 24M 25M 25M 26M 25M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 3M 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 46M 49M 77M 48M 24M 1M -2M 1M 827 000 793 000 16M 16M 32M 19M
totalNonCurrentAssets 68M 66M 96M 68M 45M 21M 22M 21M 23M 25M 41M 41M 58M 43M
otherAssets 0 0 0 0 1 1 0 0 0 0 0 0 0 0
totalAssets 1 059M 821M 885M 902M 904M 832M 789M 818M 916M 979M 760M 873M 882M 961M
accountPayables 39M 54M 39M 43M 38M 27M 38M 18M 28M 31M 37M 14M 17M 8M
shortTermDebt 101M 7M 0 14M 12M 84M 0 6M 6M 6M 0 5M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 2M 2M 4M 0 117M 98M 0 0 0 0 0
otherCurrentLiabilities 140M 139M 0 133M 117M 101M 76M 45M 44M 101M 81M 96M 8M 4M
totalCurrentLiabilities 280M 201M 186M 191M 169M 215M 248M 186M 175M 139M 168M 115M 132M 128M
longTermDebt 375M 462M 453M 464M 468M 338M 93M 104M 105M 106M 93M 108M 189M 359M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 3M 2M 8M 10M 3M 12M 242M 296M 290M 322M 316M 431M 345M 254M
totalNonCurrentLiabilities 378M 464M 471M 473M 471M 350M 347M 400M 395M 428M 423M 450M 551M 628M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 21M 16M 17M 18M 17M 10M 18M 17M 18M 19M 20M 21M 21M 19M
totalLiabilities 658M 665M 657M 665M 640M 565M 594M 586M 570M 567M 590M 565M 683M 756M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 12 000 12 000 12 000 12 000 12 000 12 000 12 000 12 000 12 000 12 000 11 000 11 000 10000 8000
retainedEarnings -2 954M -3 170M -3 035M -2 999M -2 942M -2 904M -2 837M -2 749M -2 609M -2 487M -2 309M -2 143M -1 657M -926M
accumulatedOtherComprehensiveIncomeLoss -2M -3M -3M -3M -3M -4M -4M -1M -796 000 -775 000 -875 000 -3M -2M -116 999
othertotalStockholdersEquity 3 358M 3 329M 3 239M 3 209M 3 174M 2 982M 2 955M 2 900M 2 453M
totalStockholdersEquity 401M 156M 229M 237M 264M 267M 195M 232M 345M 412M 170M 307M 199M 205M
totalEquity 401M 156M 229M 237M 264M 267M 195M 232M 345M 412M 170M 307M 199M 205M
totalLiabilitiesAndStockholdersEquity 1 059M 821M 902M 904M 832M 818M 916M 979M 873M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 059M 821M 885M 902M 904M 832M 789M 818M 916M 979M 760M 873M 882M 961M
totalInvestments 0 0 5M 0 8M 8M 4M 13M 9M 0 0 124M 61M 312M
totalDebt 475M 470M 470M 470M 475M 431M 111M 110M 111M 112M 113M 113M 210M 378M
netDebt -4M 98M 58M 74M 113M 104M -240M -343M -505M -653M -439M -471M -430M -188M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-27 2023-02-21 2022-02-28 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 272M 206M 8M 80M 25M
otherReceivables 0 0 0 0 0
prepaids 10M 39M 36M 5M 3M
totalPayables 39M 38M 37M 17M 8M
otherPayables 0 0 0 0 0
accruedExpenses 140M 128M 43M 103M 112M
capitalLeaseObligationsCurrent 7M 6M 6M 4M 4M
capitalLeaseObligationsNonCurrent 10M 11M 14M 17M 15M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 3 267M 3 036M 2 480M 1 857M 1 131M
otherTotalStockholdersEquity -1 0 0 -1 -1

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS APLS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-31 2024-11-05 2024-08-01 2024-05-07 2023-11-01 2023-07-31 2023-05-04 2022-11-07
acceptedDate 2025-10-30 06:57:30 2025-07-31 06:52:59 2025-02-28 07:00:18 2024-11-05 06:57:32 2024-08-01 07:02:24 2024-05-07 07:02:51 2024-02-27 07:01:54 2023-11-01 07:02:15 2023-07-31 16:07:17 2023-05-04 16:02:25 2023-02-21 16:09:51 2022-11-07 16:13:20 2022-02-28 16:06:11 2021-02-25 16:01:27
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 216M -42M -198M -57M -38M -66M -529M -140M -122M -178M -652M -191M -746M -345M
depreciationAndAmortization 339 000 446 000 2M 457 000 449 000 444 000 2M 405 000 410 000 399 000 1M 357 000 1M 859 000
deferredIncomeTax 0 0 0 0 0 0 0 133 000 0 0 0 0 198M 0
stockBasedCompensation 28M 27M 114M 27M 30M 30M 106M 22M 29M 29M 91M 24M 71M 45M
changeInWorkingCapital -136M 18M -18M 63M -6M -103M -200M -57M -64M -36M -16M -28M -94M 20M
accountsReceivables -131M 21M -58M 25M -37M -61M 0 -58M -79M -24M 2M -574 000 -10M 0
inventory 5M -26M -11M 9M -15M -15M 0 5M -18M 144 000 -69M -11M -16M 0
accountsPayables -16M -1M 1M -1M 11M -11M 170 000 -10M -4M -6M 19M -7M 10M -54 000
otherWorkingCapital 5M 24M 50M 30M 33M -16M -200M 6M 37M 29M 33M -9M -78M 20M
otherNonCashItems 636 000 614 000 12M 822 000 76M 124M 26M 6M 7M 7M 62M 41M 6M 119M
netCashProvidedByOperatingActivities 108M 4M -88M 34M -8M -133M -595M -169M -150M -178M -514M -154M -563M -160M
investmentsInPropertyPlantAndEquipment -148 000 -49 000 -403 000 0 -90 000 -293 000 -773 000 -47 000 -372 000 -259 000 -2M -196 000 -1M -5M
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 -61M 0 -249M 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 -332M 0 -171M -879M
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 393M 125M 420M 568M
otherInvestingActivites 0 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites -148 000 -49 000 0 -90 000 -293 000 -47 000 -372 000 -259 000 125M
debtRepayment 0 0 0 0 -99M 0 -25M 0 0
commonStockIssued 797 000 7M -15M -99M 9M 6M 26M 384M 0
commonStockRepurchased 0 0 0 3M 0 -28 000 0 -11 000 -28 000 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 -2M 0 0
otherFinancingActivites -4000 0 3M 42M -28 000 -11 000 2M 7M 10M
netCashUsedProvidedByFinancingActivities 793 000 7M 3M 42M 108M 6M 2M 391M 10M
effectOfForexChangesOnCash 22 000 685 000 -659 000 173 000 342 000 -209 000 135 000 -458 000 -47 000 56 000 -488 000 -310 000 -2M 359 000
netChangeInCash 109M 12M 60M 37M 34M -25M -201M -164M -149M 213M -89M -20M 75M 215M
cashAtEndOfPeriod 481M 371M 413M 398M 361M 327M 352M 454M 617M 766M 553M 585M 642M 567M
cashAtBeginningOfPeriod 371M 360M 352M 361M 327M 352M 553M 617M 766M 553M 642M 606M 567M 352M
operatingCashFlow 108M 4M -88M 34M -8M -133M -595M -169M -150M -178M -514M -154M -563M -160M
capitalExpenditure -148 000 -49 000 -403 000 0 -90 000 -293 000 -773 000 -47 000 -372 000 -259 000 -2M -196 000 -1M -5M
freeCashFlow 108M 4M -88M 34M -8M -133M -596M -169M -151M -178M -515M -155M -564M -166M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-27 2023-02-21 2022-02-28 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 99 000 61M 249M 0
netCashProvidedByInvestingActivities -403 000 -674 000 60M 248M -317M
netDebtIssuance 365M 0 0 0 323M
longTermNetDebtIssuance 365M 0 0 0 323M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 19M 384M 380M 380M 381M
netCommonStockIssuance 19M 384M 380M 380M 381M
commonStockIssuance 19M 384M 380M 380M 381M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -235M 10M -14M 12M -12M
netCashProvidedByFinancingActivities 149M 394M 366M 392M 692M
incomeTaxesPaid 2M 0 5M 49 000 0
interestPaid 29M 0 5M 10M 13M

Earning call transcript

2025 q3
2025-10-30 ET (fiscal 2025 q3)
2025 q2
2025-08-02 ET (fiscal 2025 q2)
2025 q1
2025-05-07 ET (fiscal 2025 q1)
2024 q4
2025-02-28 ET (fiscal 2024 q4)
2024 q3
2024-11-05 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-27 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-07-31 ET (fiscal 2023 q2)
2023 q1
2023-05-06 ET (fiscal 2023 q1)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-01-12 21:52 ET
Apellis Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-12 21:52 ET
Apellis Pharmaceuticals published news for 2025 q4
SEC form 10
2025-10-30 10:57 ET
Apellis Pharmaceuticals reported for 2025 q3
SEC form 10
2025-07-31 10:52 ET
Apellis Pharmaceuticals reported for 2025 q2
SEC form 10
2025-05-07 11:01 ET
Apellis Pharmaceuticals reported for 2025 q1
SEC form 10
2025-05-07 00:00 ET
Apellis Pharmaceuticals published news for 2025 q1
SEC form 10
2025-02-28 12:00 ET
Apellis Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-28 00:00 ET
Apellis Pharmaceuticals reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Apellis Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Apellis Pharmaceuticals published news for 2024 q4
SEC form 10
2024-11-05 06:57 ET
Apellis Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-01 07:02 ET
Apellis Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Apellis Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-07 07:02 ET
Apellis Pharmaceuticals reported for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Apellis Pharmaceuticals published news for 2024 q1
SEC form 8
2024-02-27 07:30 ET
Apellis Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-27 07:30 ET
Apellis Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-27 07:01 ET
Apellis Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Apellis Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Apellis Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Apellis Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-01 07:02 ET
Apellis Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-01 00:00 ET
Apellis Pharmaceuticals published news for 2023 q3
SEC form 8
2023-10-05 00:00 ET
Apellis Pharmaceuticals published news for 2023 q3
SEC form 10
2023-07-31 16:07 ET
Apellis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-31 08:03 ET
Apellis Pharmaceuticals reported for 2023 q2
SEC form 8
2023-07-31 00:00 ET
Apellis Pharmaceuticals published news for 2023 q2
SEC form 10
2023-07-31 00:00 ET
Apellis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-17 16:14 ET
Apellis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-01 16:10 ET
Apellis Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Apellis Pharmaceuticals published news for 2023 q1
SEC form 10
2023-02-21 00:00 ET
Apellis Pharmaceuticals reported for 2022 q4
SEC form 10
2022-11-07 00:00 ET
Apellis Pharmaceuticals reported for 2022 q3
SEC form 10
2022-08-08 00:00 ET
Apellis Pharmaceuticals reported for 2022 q2
SEC form 10
2022-05-04 00:00 ET
Apellis Pharmaceuticals reported for 2022 q1
SEC form 10
2022-02-28 00:00 ET
Apellis Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Apellis Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-08 00:00 ET
Apellis Pharmaceuticals published news for 2021 q3
SEC form 10
2021-08-09 00:00 ET
Apellis Pharmaceuticals published news for 2021 q2
SEC form 10
2021-04-28 00:00 ET
Apellis Pharmaceuticals published news for 2021 q1